TITLE

New Tuberculosis Therapeutics: A Growing Pipeline

AUTHOR(S)
Spigelman, Melvin K.
PUB. DATE
August 2007
SOURCE
Journal of Infectious Diseases;8/15/2007 Supplement, Vol. 196, pS28
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Novel chemotherapeutic drugs are needed to improve tuberculosis (TB) control, especially in the developing world. Given the magnitude of the problem and the resources available in countries that have the highest burden of disease, the present standards of care for the treatment of drug-susceptible TB, drug-resistant TB, TB/human immunodeficiency virus (HIV) coinfection, and latent TB infection are all unsatisfactory. Because no truly novel compounds for the treatment of TB have been discovered in the past 40 years, the recent enhanced activity in the research and development of new TB drugs is extremely encouraging. Seven compounds are presently in clinical development specifically for the treatment of TB. Other known antibiotic compound families are being investigated preclinically, in an attempt to identify new antimicrobial drugs with specific antituberculous activity. In addition, novel targets have been identified and are the subject of efforts to validate their potential usefulness in the treatment of TB.
ACCESSION #
26450006

 

Related Articles

  • Challenges in tuberculosis drug research and development. Ginsberg, Ann M.; Spigelman, Melvin // Nature Medicine;Mar2007, Vol. 13 Issue 3, p290 

    The article discusses the challenges faced by researchers in tuberculosis (TB) drug research and development. The early part of the twenty-first century has seen a reawakening of drug research and development for TB, spurred on by an urgent need to stem the tide of the disease globally and...

  • Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in Open Science. Badiola, Katrina A.; Quan, Diana H.; Triccas, James A.; Todd, Matthew H. // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Tuberculosis afflicts an estimated 2 billion people worldwide and causes 1.3 million deaths annually. Chemotherapeutic solutions rely on drugs developed many years ago, with only one new therapeutic having been approved in the last 40 years. Given the rise of drug-resistant strains, there is an...

  • Postsanatorium Pattern of Antituberculous Drug Resistance in the Canadian-born Population of Western Canada: Effect of Outpatient Care and Immigration. Long, Richard; Chui, Linda; Kakulphimp, Jocelyne; Zielinski, Michele; Talbot, James; Kunimoto, Dennis // American Journal of Epidemiology;May2001, Vol. 153 Issue 9, p903 

    Concurrent with the shift in tuberculosis case management from sanatorium to outpatient setting was a shift in the continent of origin (Europe to Asia) of most new immigrants to Canada. To assess the impact of these two events on antituberculous drug resistance in the Canadian-born population,...

  • Birinci KuÅŸak Antitüberküloz Ilaç Duyarlılık Testlerinde Dış Kalite Kontrol Uygulaması: Ön DeÄŸerlendirme Çalışması. Ceyhan, İsmail; Şimşek, Hülya; Tarhan, Gülnur; Güner, Uğur // Klimik Journal / Klimik Dergisi;Dec2010, Vol. 23 Issue 3, p110 

    Objective: Antituberculous drug resistance is a major problem in ensuring the achievement of Tuberculosis Control Programs (TCP). World Health Organization (WHO) has stressed that the quality assurance for the Drug Susceptibility Tests (DST) used for obtaining confidential results and to form...

  • BRIEF HISTORY ON TUBERCULOSIS CONTROL POLICIES. Andrade, Hamilton Leandro Pinto de; Enders, Bertha Cruz; Miranda, Francisco Arnoldo Nunes de // Journal of Nursing UFPE / Revista de Enfermagem UFPE;Jun2012, Vol. 6 Issue 6, p1468 

    Objective: to briefly describe the tuberculosis control policies in Brazil over the years. Methodology: descriptive study addressing Tuberculosis control policies through the years until today. Data was collected through reading and analyzes of articles, also through manuals of the Ministry of...

  • Spotlight on... Ken Duncan. Opar, Alisa // Nature Medicine;Mar2007, Vol. 13 Issue 3, p271 

    The article profiles Ken Duncan, senior program officer for the Bill & Melinda Gates Foundation's tuberculosis (TB) program in the U.S. Duncan's main goal is to help foster drugs that might cure TB in a matter of weeks rather than in months. There have been no new drugs for TB in nearly 40...

  • Four-month fluoroquinolonecontaining regimens are inferior to standard 6-month tuberculosis treatment. Sterling, Timothy R. // Evidence Based Medicine;Aug2015, Vol. 20 Issue 4, p128 

    In this article, the author comments on a study by S.H Gillespie related to the efficacy of fluoroquinolones in the treatment of tuberculosis. According to the study, using fluoroquinolones like moxifloxacin instead of ethambutol and isoniazid, could shorten the duration of tuberculosis...

  • Effective identification, treatment and prevention is key in the war on tuberculosis.  // Drugs & Therapy Perspectives;Nov2006, Vol. 22 Issue 11, p8 

    The incidence of tuberculosis is increasing, especially in developing countries. Antitubercular regimens include different combinations of first-line drugs that quickly kill multiplying bacilli, reducing resistance and preventing spread, followed by a longer course to eradicate semidormant...

  • Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. Udwadia, Zarir; Vendoti, Deepesh // Journal of Epidemiology & Community Health;Jun2013, Vol. 67 Issue 6, p471 

    The authors discuss totally drug-resistant tuberculosis (TDR-TB) which is a generic term for tuberculosis strains are resistant to drugs than strains classified as extensively drug-resistant tuberculosis. They mention that TDR-TB in India has resulted from further mutations within the bacterial...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics